Blueprint Medicines (BPMC) “announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis. Key results continue to position AYVAKIT(R)/AYVAKYT as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>